Catalyst Pharmaceuticals (NASDAQ: CPRX) reported second quarter EPS of $0.680, $0.29 more than the analyst estimate of $0.390.
Revenue for the quarter totaled $146.54M, compared to the average estimate of $140.22M.
Achieved Q2 2025 record total revenue of $146.6M, an increase of 19.4% year-over-year, marking another quarter of consecutive growth
Reported record revenue for the first half of 2025 of $288.0 million, an increase of 30.2% year-on-year
Confirms full-year 2025 total sales guidance of $545 million to $565 million, reflecting broad-based growth and continued demand
FIRDAPSE® Q2 2025 net product sales of $84.8 million, up 9.7% YoY; net product sales of $168.6 million in the first half of 2025, up 16.9% YoY, highlighting continued momentum and confidence in long-term growth
AGAMREE® Q2 2025 net product sales of USD 27.4 million, 212.9% year-on-year; net product sales of USD 49.4 million in the first half of 2025, an increase of 398.0% year-on-year, underlining continued product momentum
FYCOMPA® Q2 2025 net product sales of USD 34.3 million; slight decrease in prior year due to generic entry following loss of exclusivity
Strong cash position of USD 652.8 million and no funded debt at the end of Q2 2025
